lncRNA TUG1 Promotes Cisplatin Resistance by Regulating CCND2 via Epigenetically Silencing miR-194-5p in Bladder Cancer

• Published in: Molecular therapy. Nucleic acids Vol. 16; pp. 257 - 271
• Main Authors: Yu, Gan, Zhou, Hui, Yao, Weimin, Meng, Lirong, Lang, Bin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07.06.2019; Elsevier Limited; American Society of Gene & Cell Therapy; Elsevier
• Subjects: Apoptosis; Azacytidine; Biomarkers; Bladder cancer; Cancer; Cancer therapies; CCND2; Cell growth; Cell proliferation; Chemoresistance; Chemotherapy; Cisplatin; cisplatin resistance; Deoxyribonucleic acid; DNA; DNA methylation; Experiments; EZH2; Gene expression; Lung cancer; Lymphatic system; Medical prognosis; Metastases; methylation; miR-194-5p; Survival analysis; Taurine; Therapeutic applications; TUG1; Tumorigenesis; China; chemoresistance; CCND2; bladder cancer; cisplatin resistance; methylation; miR-194-5p; TUG1; EZH2

Taurine-upregulated gene 1 (TUG1) has been involved in tumorigenesis of several human cancers, but its precise biological role in bladder cancer remains largely elusive. In this study, we found that TUG1 was upregulated in bladder cancer and the expression of TUG1 was positively and negatively corre...